Edgar Filing: Akers Biosciences Inc - Form 4

Akers Biosciences Inc

Form 4											
December 31	, 2015										
									PPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
	Check this box							Expires:	January 31, 2005		
if no longer subject to Section 16. Form 4 or				GES IN BENEFICIAL OWNERSHIP OF SECURITIES					Estimated average burden hours per		
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,						e Act of 1934,	response	0.5			
obligation may conti <i>See</i> Instru 1(b).	nue. Section 170	(a) of the		ility Hold	ling Com	pany	Act of	f 1935 or Sectio	n		
(Print or Type R	esponses)										
1. Name and Address of Reporting Person * 2. Issuer KNOX BRANDON THOMAS Symbol			r Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer				
			Akers B	Biosciences Inc [AKER]				(Check all applicable)			
(Last)	(First) (Middle)	3. Date of	Earliest Tr	ansaction					,	
			(Month/D 12/30/20	-				XDirector10% Owner Officer (give titleOther (specify below)below)			
(Street) 4. If Amer			endment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mon VILLANOVA, PA 19085									e) by One Reporting Person by More than One Reporting		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acc	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if		3.4. Securities AcquiredTransaction(A) or Disposed ofCode(D)(Instr. 8)(Instr. 3, 4 and 5)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common	10/00/0015			Code V	Amount 55,000	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	D		
Stock	12/30/2015			А	<u>(1)</u>	A	\$0	138,076	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Titl Deriva Securi (Instr.	ative ity	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	of Deri Secu Acq (A) Disp of (I (Inst	orNumber Expiration of (Month/I			e Amount of		Derivative D Security S (Instr. 5) B O F R R T	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
					Code V	/ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Akers Biosciences Inc - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
KNOX BRANDON THOMAS								
771 EAGLE ROAD	Х							
VILLANOVA, PA 19085								
Signatures								
/s/ Brandon Thomas Knox	12/30/201	5						
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Such shares were issued under Akers Biosciences, Inc.'s Amended and Restated 2013 Incentive Stock and Award Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.